{"pmid":32294258,"title":"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","text":["SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID-19 in this delicate population concerns.","J Eur Acad Dermatol Venereol","Messina, F","Piaserico, S","32294258"],"abstract":["Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID-19 in this delicate population concerns."],"journal":"J Eur Acad Dermatol Venereol","authors":["Messina, F","Piaserico, S"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294258","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16468","keywords":["SARS-CoV-2","biologic","covid-19","guselkumab","psoriasis"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664266295554605056,"score":8.233237,"similar":[{"pmid":32300516,"pmcid":"PMC7160052","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32300516"],"abstract":["With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300516","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s13555-020-00377-9","keywords":["biologics","covid-19","coronavirus","infection","pandemic","psoriasis","sars-cov-2"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664357978581499904,"score":83.784546},{"pmid":32297987,"title":"Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection.","text":["Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection.","The spread of the novel-Coronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized anti-human inteleukine-6 receptor antibody tocilizumab seems a promising strategy for these patients. This article is protected by copyright. All rights reserved.","J Med Virol","Di Giambenedetto, Simona","Ciccullo, Arturo","Borghetti, Alberto","Gambassi, Giovanni","Landi, Francesco","Visconti, Elena","Zileri Dal Verme, Lorenzo","Bernabei, Roberto","Tamburrini, Enrica","Cauda, Roberto","Gasbarrini, Antonio","32297987"],"abstract":["The spread of the novel-Coronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized anti-human inteleukine-6 receptor antibody tocilizumab seems a promising strategy for these patients. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Di Giambenedetto, Simona","Ciccullo, Arturo","Borghetti, Alberto","Gambassi, Giovanni","Landi, Francesco","Visconti, Elena","Zileri Dal Verme, Lorenzo","Bernabei, Roberto","Tamburrini, Enrica","Cauda, Roberto","Gasbarrini, Antonio"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297987","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25897","keywords":["COVID-19","SARS-CoV-2","interstitial pneumonia","tocilizumab"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664266651242070016,"score":76.11288},{"pmid":32282977,"title":"First case of COVID-19 in a kidney transplant recipient treated with belatacept.","text":["First case of COVID-19 in a kidney transplant recipient treated with belatacept.","Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing public health emergency of international concern. Acute respiratory distress syndrome (ARDS) develops in 3-30% of patients with COVID-19 (1,2), because of direct virus-induced cytopathic effects in the respiratory tract or cytokine storms triggered by the host's immune response. Comorbidities are known to increase the risk of ARDS in SARS-CoV-2-infected patients (1).","Am J Transplant","Marx, David","Moulin, Bruno","Fafi-Kremer, Samira","Benotmane, Ilies","Gautier, Gabriela","Perrin, Peggy","Caillard, Sophie","32282977"],"abstract":["Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing public health emergency of international concern. Acute respiratory distress syndrome (ARDS) develops in 3-30% of patients with COVID-19 (1,2), because of direct virus-induced cytopathic effects in the respiratory tract or cytokine storms triggered by the host's immune response. Comorbidities are known to increase the risk of ARDS in SARS-CoV-2-infected patients (1)."],"journal":"Am J Transplant","authors":["Marx, David","Moulin, Bruno","Fafi-Kremer, Samira","Benotmane, Ilies","Gautier, Gabriela","Perrin, Peggy","Caillard, Sophie"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282977","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15919","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664182200668520448,"score":65.812096},{"pmid":32056407,"pmcid":"PMC7025910","title":"Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.","text":["Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.","Since mid-December of 2019, coronavirus disease 2019 (COVID-19) infection has been spreading from Wuhan, China. The confirmed COVID-19 patients in South Korea are those who came from or visited China. As secondary transmissions have occurred and the speed of transmission is accelerating, there are rising concerns about community infections. The 54-year old male is the third patient diagnosed with COVID-19 infection in Korea. He is a worker for a clothing business and had mild respiratory symptoms and intermittent fever in the beginning of hospitalization, and pneumonia symptoms on chest computerized tomography scan on day 6 of admission. This patient caused one case of secondary transmission and three cases of tertiary transmission. Hereby, we report the clinical findings of the index patient who was the first to cause tertiary transmission outside China. Interestingly, after lopinavir/ritonavir (Kaletra, AbbVie) was administered, beta-coronavirus viral loads significantly decreased and no or little coronavirus titers were observed.","J Korean Med Sci","Lim, Jaegyun","Jeon, Seunghyun","Shin, Hyun Young","Kim, Moon Jung","Seong, Yu Min","Lee, Wang Jun","Choe, Kang Won","Kang, Yu Min","Lee, Baeckseung","Park, Sang Joon","32056407"],"abstract":["Since mid-December of 2019, coronavirus disease 2019 (COVID-19) infection has been spreading from Wuhan, China. The confirmed COVID-19 patients in South Korea are those who came from or visited China. As secondary transmissions have occurred and the speed of transmission is accelerating, there are rising concerns about community infections. The 54-year old male is the third patient diagnosed with COVID-19 infection in Korea. He is a worker for a clothing business and had mild respiratory symptoms and intermittent fever in the beginning of hospitalization, and pneumonia symptoms on chest computerized tomography scan on day 6 of admission. This patient caused one case of secondary transmission and three cases of tertiary transmission. Hereby, we report the clinical findings of the index patient who was the first to cause tertiary transmission outside China. Interestingly, after lopinavir/ritonavir (Kaletra, AbbVie) was administered, beta-coronavirus viral loads significantly decreased and no or little coronavirus titers were observed."],"journal":"J Korean Med Sci","authors":["Lim, Jaegyun","Jeon, Seunghyun","Shin, Hyun Young","Kim, Moon Jung","Seong, Yu Min","Lee, Wang Jun","Choe, Kang Won","Kang, Yu Min","Lee, Baeckseung","Park, Sang Joon"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32056407","week":"20207|Feb 10 - Feb 16","doi":"10.3346/jkms.2020.35.e79","keywords":["COVID-19","Coronavirus","Pneumonia","Real-Time Reverse-Transcriptase Polymerase Chain Reaction","Tertiary Infection","Viral Load"],"link_comment_in":"32080993","source":"PubMed","locations":["Wuhan","China","South Korea"],"countries":["Korea, Republic of","China"],"countries_codes":["KOR|Korea, Republic of","CHN|China"],"topics":["Case Report"],"weight":1,"e_drugs":["Ritonavir","Lopinavir"],"_version_":1663352134656065536,"score":61.90646},{"pmid":32304393,"title":"Contributory Role of Positron Emission Tomography in a Left Ventricular Assist Device Recipient at the time of COVID-19 pandemic.","text":["Contributory Role of Positron Emission Tomography in a Left Ventricular Assist Device Recipient at the time of COVID-19 pandemic.","We report on the role of fluorine 18-fluorodeoxyglucose (F-FDG) positron emission tomography (PET) scan examinations to contribute in the diagnosis of COVID-19 respiratory syndrome even in the case of asymptomatic left ventricular assist device (LVAD) recipients. Thus, warm caution and thoughtful approaches for timely detection should be taken for our delicate LVAD population expecially if patients are currently living in a high density COVID-19 infected area and the pontential intention for LVAD treatment is bridge to transplantation.","ASAIO J","Loforte, Antonio","Gliozzi, Gregorio","Martin Suarez, Sofia","Pacini, Davide","32304393"],"abstract":["We report on the role of fluorine 18-fluorodeoxyglucose (F-FDG) positron emission tomography (PET) scan examinations to contribute in the diagnosis of COVID-19 respiratory syndrome even in the case of asymptomatic left ventricular assist device (LVAD) recipients. Thus, warm caution and thoughtful approaches for timely detection should be taken for our delicate LVAD population expecially if patients are currently living in a high density COVID-19 infected area and the pontential intention for LVAD treatment is bridge to transplantation."],"journal":"ASAIO J","authors":["Loforte, Antonio","Gliozzi, Gregorio","Martin Suarez, Sofia","Pacini, Davide"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304393","week":"202016|Apr 13 - Apr 19","doi":"10.1097/MAT.0000000000001176","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664431720530706432,"score":61.253212}]}